Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

被引:0
|
作者
Mark A. Geyer
Kirsten Krebs-Thomson
David L. Braff
Neal R. Swerdlow
机构
[1] Department of Psychiatry-0804,
[2] University of California,undefined
[3] San Diego,undefined
[4] 9500 Gilman Drive,undefined
[5] La Jolla,undefined
[6] CA 92093-0804,undefined
[7] USA,undefined
来源
Psychopharmacology | 2001年 / 156卷
关键词
Startle Prepulse inhibition Animal Rat Schizophrenia;
D O I
暂无
中图分类号
学科分类号
摘要
Rationale: Patients with schizophrenia exhibit deficits in an operational measure of sensorimotor gating: prepulse inhibition (PPI) of startle. Similar deficits in PPI are produced in rats by pharmacological or developmental manipulations. These experimentally induced PPI deficits in rats are clearly not animal models of schizophrenia per se, but appear to provide models of sensorimotor gating deficits in schizophrenia patients that have face, predictive, and construct validity. In rodents, disruptions in PPI of startle are produced by: stimulation of D2 dopamine (DA) receptors, produced by amphetamine or apomorphine; activation of serotonergic systems, produced by serotonin (5-HT) releasers or direct agonists at multiple serotonin receptors; and blockade of N-methyl-D-aspartate (NMDA) receptors, produced by drugs such as phencyclidine (PCP). Accordingly, dopaminergic, serotonergic, and glutamatergic models of disrupted PPI have evolved and have been applied to the identification of potential antipsychotic treatments. In addition, some developmental manipulations, such as isolation rearing, have provided non-pharmacological animal models of the PPI deficits seen in schizophrenia. Objective: This review summarizes and evaluates studies assessing the effects of systemic drug administrations on PPI in rats. Methods: Studies examining systemic drug effects on PPI in rats prior to January 15, 2001 were compiled and organized into six annotated appendices. Based on this catalog of studies, the specific advantages and disadvantages of each of the four main PPI models used in the study of antipsychotic drugs were critically evaluated. Results: Despite some notable inconsistencies, the literature provides strong support for significant disruptions in PPI in rats produced by DA agonists, 5-HT2 agonists, NMDA antagonists, and isolation rearing. Each of these models exhibits sensitivity to at least some antipsychotic medications. While the PPI model based on the effects of direct DA agonists is the most well-validated for the identification of known antipsychotics, the isolation rearing model also appears to be sensitive to both typical and atypical antipsychotics. The 5-HT PPI model is less generally sensitive to antipsychotic medications, but can provide insight into the contribution of serotonergic systems to the actions of newer antipsychotics that act upon multiple receptors. The deficits in PPI produced by NMDA antagonists appear to be more sensitive to clozapine-like atypical antipsychotics than to typical antipsychotics. Hence, despite some exceptions to this generalization, the NMDA PPI model might aid in the identification of novel or atypical antipsychotic medications. Conclusions: Studies of drug effects on PPI in rats have generated four distinctive models that have utility in the identification of antipsychotic medications. Because each of these models has specific advantages and disadvantages, the choice of model to be used depends upon the question being addressed. This review should help to guide such decisions.
引用
收藏
页码:117 / 154
页数:37
相关论文
共 50 条
  • [11] Altered prepulse inhibition in rats treated prenatally with the antimitotic Ara-C: an animal model for sensorimotor gating deficits in schizophrenia
    Elmer, GI
    Sydnor, J
    Guard, H
    Hercher, E
    Vogel, MW
    PSYCHOPHARMACOLOGY, 2004, 174 (02) : 177 - 189
  • [12] Sensorimotor gating deficits in "two-hit" models of schizophrenia risk factors
    Khan, Asma
    Powell, Susan B.
    SCHIZOPHRENIA RESEARCH, 2018, 198 : 68 - 83
  • [13] Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review
    Weiss, IC
    Feldon, J
    PSYCHOPHARMACOLOGY, 2001, 156 (2-3) : 305 - 326
  • [14] Environmental animal models for sensorimotor gating deficiencies in schizophrenia: a review
    Isabelle C. Weiss
    Joram Feldon
    Psychopharmacology, 2001, 156 : 305 - 326
  • [15] Sensorimotor gating and anxiety: Prepulse inhibition following acute exercise
    Duley, Aaron R.
    Hillman, Charles H.
    Coombes, Stephen
    Janelle, Christopher M.
    INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, 2007, 64 (02) : 157 - 164
  • [16] Prepulse inhibition as a measure of sensorimotor gating in Parkinson's disease
    Karayanidis, F
    Schall, U
    Johnston, P
    INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY, 2004, 54 (1-2) : 120 - 121
  • [17] Mouse genetic models for sensorimotor gating deficits
    Paylor, R
    BIOLOGICAL PSYCHIATRY, 2000, 47 (08) : 123S - 123S
  • [18] CLONIDINE NORMALIZES SENSORIMOTOR GATING DEFICITS IN CHRONIC PATIENTS WITH SCHIZOPHRENIA
    Oranje, Bob
    Glenthoj, Birte Y.
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 364 - 364
  • [19] Prepulse inhibition deficits in schizophrenia are modified by smoking status
    Woznica, Andrea A.
    Sacco, Kristi A.
    George, Tony P.
    SCHIZOPHRENIA RESEARCH, 2009, 112 (1-3) : 86 - 90
  • [20] Gender effects in prepulse inhibition and facilitation deficits in schizophrenia
    Kumari, V
    Aasen, I
    Sharna, T
    SCHIZOPHRENIA RESEARCH, 2003, 60 (01) : 254 - 254